Exercise of Options; PDMR Dealing

RNS Number : 7691Q

IXICO plc

01 March 2021

 

IXICO plc

("IXICO" or the "Company")

Exercise of Options; PDMR Dealing

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it received notification on 1 March 2021 that Giulio Cerroni , CEO and PDMR , exercised 676,582 share options with an exercise price of 36.5p.  Of the newly created shares, 294,849 were sold at a price of 84p per share solely in order to meet the exercise cost of these share options.  Following this transaction Giulio Cerroni, CEO and PDMR, increases his shareholding in IXICO from 109,600 shares to 491,333 shares.

Application has been made to the London Stock Exchange for the admission to trading on AIM the 676,582 new ordinary shares of 1p each ("New Shares") to satisfy the exercise of options. The New Shares are expected to be admitted to trading on AIM on 4 March 2021.

Total voting rights

Application has been made for admission to trading on AIM of 676,582 New Shares. Following Admission of the New Shares on AIM there will be in total 47,969,521 ordinary shares in the capital of the Company in issue, each carrying equal voting rights.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IXICO under the FCA's Disclosure and Transparency Rules.

The below makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

Details of PDMR transaction

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Giulio Cerroni
2	Reason for the notification
a)	Position/status	PDMR (CEO)
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	IXICO plc
b)	LEI	2138005M1F59O6HWSA97
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares in IXICO plc
	Identification code	GB00BCLY7L40
b)	Nature of the transaction	Exercise of options
c)	Price(s) and volume(s)
			Exercise Price(s)	Volume(s)
			36.5p	676,582
d)	Aggregated information
	- Aggregated volume	n/a
	- Price
e)	Date of the transaction	1 March 2021
f)	Place of the transaction	N/A

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Giulio Cerroni
2	Reason for the notification
a)	Position/status	PDMR (CEO)
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	IXICO plc
b)	LEI	2138005M1F59O6HWSA97
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares in IXICO plc
	Identification code	GB00BCLY7L40
b)	Nature of the transaction	Sale
c)	Price(s) and volume(s)
			Date	Price(s)	Volume(s)
			1/03/21	84.0p	294,849
d)	Aggregated information
	- Aggregated volume	n/a
	- Price
e)	Date of the transaction	1 March 2021
f)	Place of the transaction	London Stock Exchange

For further information please contact:

IXICO plc			[phone]
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)				[phone]
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales
Walbrook PR Ltd	[phone]
Paul McManus / Lianne Cawthorne /		[e-mail]
Alice Woodings

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

More information is available on www.IXICO.com   and follow us on Twitter @IxicOplc  

 

END

 

 

MSCDKDBBOBKDBNK